Results 111 to 120 of about 5,881 (166)

A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming. [PDF]

J Transl Med
Zhang W, Shi L, Li Y, He C, Cui S, Liu Y, Wang X, Liu L, Gao Y, Diao L, Wu L, Yao Y, Feng Y, Wu X, Yin S, Li W, Song B, Huang C.   +17 more
europepmc   +1 more source

Screening of the Pandemic Response Box Library Identified CRM1/XPO1 as an Anti-Mammarenavirus Druggable Target. [PDF]

Viruses
Ofodile CA, Cubitt B, Onyemelukwe N, Okwuanaso CB, Witwit H, de la Torre JC.   +5 more
europepmc   +1 more source

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors. [PDF]

Neurooncol Pediatr
Refaat A, Cho HP, Williams JS, Stripay J, Blankenship K, Mercer KS, De Vries R, Connelly M, Ganguly D, Robinson S, Savage E, Twarog NR, Attery A, Laha D, Yu K, Poudel S, Dhanda SK, Stewart CF, Freeman BB, Roberts CWM, Tinkle C, Stewart EA, Upadhyaya SA, Shelat AA, Roussel MF.   +24 more
europepmc   +1 more source

<i>KRAS</i> under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition. [PDF]

Transl Lung Cancer Res
Falk M, Schatz S, Tiemann M, Ficker JH, Brueckl WM.   +4 more
europepmc   +1 more source

[Advances in ribosome biogenesis and targeted therapies for diffuse large B-cell lymphomas]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Yue MX, Zhao WL, Wang L.
europepmc   +1 more source

XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance. [PDF]

Cancer Res
Totiger TM, Chiraphapphaiboon W, Baca Y, Chaudhry S, Notti RQ, Montoya S, Chojnacka M, Gaidosh G, Afaghani J, Affer M, Armstrong C, Kavanaugh PM, Karaca E, Zabroski J, Lewis M, Maye A, Jahn J, Soni RK, Bilbao D, Walker P, Elliott A, Lou E, El-Deiry WS, Rodriguez JA, Nguyen HD, Taylor J.   +25 more
europepmc   +1 more source

Inhibition of XPO1 by selinexor enhances terminal erythroid maturation through modulation of HSP70 trafficking in severe β0-thalassemia/HbE. [PDF]

PLoS One
Khamphikham P, Tantiworawit A, Anuchapreeda S.   +2 more
europepmc   +1 more source

XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in <i>IDH</i> wildtype glioblastoma. [PDF]

Front Oncol
Mapunda JA, Suzuki Y, Burgenske D, Decker PA, Zhang L, Eckel-Passow JE, Sarkaria JN, Kitange GJ.   +7 more
europepmc   +1 more source

Targeting XPO1: A new perspective for malignant solid tumor especially small cell lung cancer. [PDF]

Chin Med J (Engl)
Zhang S, Li H, Zhao P, Yao J, Cheng Y.
europepmc   +1 more source

Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer. [PDF]

Int J Mol Sci
Paulson AL, Elmorsi RM, Lee AM, Huang RS.   +3 more
europepmc   +1 more source